ABBV closed Tuesday at $263.29, down 1.1% on the day and off 0.7% for the week, as the post-JUVMO approval glow fades and the market shifts attention to October 29 earnings.
The short-side story continues to tell a quiet tale. Short interest has fallen 7.2% over the past week and is down 21% over the past month, pulling the short interest position to just 1.04% of free float. There is nothing aggressive in that number. Borrow conditions back it up: cost to borrow has collapsed from around 0.62% in late September to 0.17%, its lowest reading in six weeks, after a brief spike that now looks like it has fully unwound. Availability is maxed out in the lending pool, with more than 1.4 billion shares available to lend against 18 million shorted, leaving no squeeze dynamic anywhere in sight. The ORTEX short score of 32 sits in the 76th percentile by rank, but in absolute terms that is a relaxed reading for a stock this size. Short sellers have been steady sellers of their positions for three weeks running, not builders.
Options positioning is mildly more cautious than usual, though not alarming. The put/call ratio ended the week at 0.84, roughly one standard deviation above its 20-day average of 0.81. That is well below the 52-week high of 1.13. It signals a modest lean toward protection rather than any concentrated bet on the downside. With Q3 results four weeks away and the stock carrying a 5% one-day loss after the July print on the record, some hedging into the period is unremarkable.
The Street remains constructively positioned, though targets are converging on a level well above the current price. The consensus still points to an average target near $279, roughly 6% above where the stock trades now. HSBC, the most bullish voice in the recent coverage cluster, carried its target to $315 in early September. Wolfe Research upgraded to Outperform in mid-August. Most of the target revisions in the past six weeks have been upward. The bull case rests on the durability of Skyrizi and Rinvoq, strong forward EPS growth expectations around 17%, and the JUVMO approval as early evidence that the Cerevel acquisition is delivering. Bears point to IRA pricing headwinds, continued Imbruvica erosion, and a portfolio that remains heavily concentrated in immunology despite acquisitions designed to broaden the mix. The 12-month forward EPS growth factor ranks in the 81st percentile, and the dividend score is near the top of the universe at 98. The EV/EBITDA multiple has drifted down modestly over 30 days to around 14.7x, a slow decompression rather than a re-rating.
On the retail attention side, the Wikimedia Foundation's Wikipedia page-views data shows attention running at a z-score of around 2.0 against ABBV's own 90-day history. That is elevated. None of the alt data series tracked for ABBV carry a measured lead against its financial results, so no directional read on the October print is possible from the available signals. The Medicaid drug utilisation data from the Centers for Medicare and Medicaid Services shows Medicaid dollars reimbursed down 10% year on year in Q1 2026, with prescriptions also down 10%, reflecting the ongoing erosion in legacy brands that the bear case centres on.
The peer group softened late in the week. INCY fell 2.9% and ALKS dropped 5.8%, while AMGN and VRTX both gained. AbbVie's modest weekly decline puts it broadly in line with the weaker half of the group, a shift from the outperformance streak that characterised August and early September. The next four weeks are shaped around one question: whether Q3 results confirm that Skyrizi growth is tracking above the consensus estimates that drove the summer rally, or whether the pricing headwinds management flagged materialise more sharply than the upgraded targets assumed.
See the live data behind this article on ORTEX.
Open ABBV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
